Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)
You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.
